Stockscreener 앱 받기
2.29
3.38%
-0.08
시간 외 거래:
2.34
0.05
+2.18%
Ernexa Therapeutics Inc 주식(ERNA)의 최신 뉴스
Sector Update: Health Care - marketscreener.com
Ernexa Therapeutics Shares Fall Pre-Bell Following Reverse Stock Split - marketscreener.com
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split - MSN
Ernexa Therapeutics announces 1-for-15 reverse stock split By Investing.com - Investing.com South Africa
Eterna Therapeutics Implements 1-for-15 Reverse Stock Split - TipRanks
Ernexa Therapeutics announces 1-for-15 reverse stock split - Investing.com
Ernexa Therapeutics registers 57M shares for resale - MSN
Ernexa therapeutics ten percent owner acquires $2.22 million in stock By Investing.com - Investing.com South Africa
Ernexa therapeutics ten percent owner acquires $2.22 million in stock - Investing.com Australia
Eterna Therapeutics Files for Resale of 57 Million Shares - marketscreener.com
Ernexa Announces 1-for-15 Reverse Stock Split Effective June 12 To Regain Nasdaq Compliance - Nasdaq
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split - citybiz
Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish - MSN
Ernexa Therapeutics Announces 1-For-15 Reverse Stock Split - marketscreener.com
Ernexa Plans 93% Share Reduction in Critical Nasdaq Compliance Move - Stock Titan
Eterna Therapeutics Completes $6M Private Placement - TipRanks
Eterna Therapeutics Increases Authorized Shares and Amends Bylaws - TipRanks
Ernexa Therapeutics announces new data to be presented at ASCO meeting 2025 - TipRanks
Ernexa Therapeutics to Present Breakthrough Data on iMSC-Based Immunotherapy at ASCO Annual Meeting 2025 - Nasdaq
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - GlobeNewswire
Revolutionary Cell Therapy Shows Promise in 'Untreatable' Ovarian Cancer: New ASCO Data Reveals Breakthrough - Stock Titan
Ernexa Therapeutics Establishes Texas Subsidiary to Support - GlobeNewswire
Ernexa's New Texas Hub Accelerates Novel Ovarian Cancer Treatment: MD Anderson Expert Leads Research - Stock Titan
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard
ERNAErnexa Latest Stock News & Market Updates - Stock Titan
Can Ernexa Crack Ovarian Cancer with Novel Stem Cell Approach? - Inside Precision Medicine
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025 - GlobeNewswire
Revolutionary Stem Cell Therapy Fights Cancer in Two Ways, MD Anderson Study Shows - Stock Titan
Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 - The Manila Times
Revolutionary Tumor-Fighting Cell Therapy: MD Anderson to Present Ernexa's Ovarian Cancer Breakthrough at AACR - Stock Titan
Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga
Ernexa Therapeutics Inc Files Prospectus For Resale Of 10.4 Million Shares Of Common Stock By Selling Stockholder- SEC Filing - marketscreener.com
Smart Trial Design In Cell Therapy: Fast-Tracking Without Compromising - Clinical Leader
Eterna therapeutics sees $394,174 stock acquisition by Charles Cherington - Investing.com Australia
ERNA stock touches 52-week low at $0.16 amid sharp annual decline - Investing.com India
Ernexa Therapeutics Closes New Funding Round - GlobeNewswire
Biotech Breakthrough: Ernexa Secures $7.25M to Advance Revolutionary Cancer Treatment - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics By Investing.com - Investing.com Australia
Eterna Therapeutics announces corporate rebranding to Ernexa Therapeutics - Investing.com
Eterna Therapeutics Changes Name to Ernexa Therapeutics to - GlobeNewswire
Major Pivot: Eterna Becomes Ernexa, Unveils New Cancer and Autoimmune Disease Strategy - Stock Titan
Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX) - MarketBeat
1.91%
1.17%
자본화:
|
볼륨(24시간):